Case report

A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma

Kentaro Masuiro\textsuperscript{a}, Genju Koh\textsuperscript{b}, So Takata\textsuperscript{a}, Shingo Nasu\textsuperscript{a}, Hiromune Takada\textsuperscript{a}, Satomo Morita\textsuperscript{a}, Ayako Tanaka\textsuperscript{a}, Takayuki Shiroyama\textsuperscript{a}, Naoko Morishita\textsuperscript{a}, Hidekazu Suzuki\textsuperscript{a}, Norio Okamoto\textsuperscript{a}, Hiromi Kawasumic, Chihiro Konishid, Tomonori Hirashima\textsuperscript{a,}\textsuperscript{\ast}

\textsuperscript{a} Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
\textsuperscript{b} Department of Oncology, Yao Tokushukai General Hospital, Osaka, Japan
\textsuperscript{c} Department of Clinical Laboratory, Osaka Habikino Medical Center, Osaka, Japan
\textsuperscript{d} Department of Pharmacy, Yao Tokushukai General Hospital, Osaka, Japan

\textbf{ARTICLE INFO}

\textbf{Keywords:}
- Lung cancer
- Follicular lymphoma
- Afatinib
- Synchronous
- Metachronous
- Double primary malignant tumors

\textbf{ABSTRACT}

The present report describes the case of a 64-year-old woman with advanced lung adenocarcinoma expressing mutant epidermal growth factor receptor (EGFR). The patient developed follicular lymphoma during treatment with the EGFR-tyrosine kinase inhibitor afatinib. Standard immunochemotherapy for follicular lymphoma was introduced in addition to continuing treatment with afatinib for lung cancer. Immunochemotherapy was effective and improved the patient's performance status while afatinib controlled the progression of lung cancer. Our case study suggests that it is safe to introduce standard immunochemotherapy for patients who develop malignant lymphoma while continuing treatment with tyrosine kinase inhibitors for lung adenocarcinoma expressing mutant EGFR.

1. Introduction

Molecular-targeted drugs such as epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and anaplastic lymphoma kinase (ALK) inhibitors have extended the life expectancy of patients with lung adenocarcinoma (LAD) \cite{1-3}. Consequently, we often encounter patients with non-small cell lung cancer (NSCLC) who developed other synchronous or metachronous malignant tumors. A number of articles reported that patients with both NSCLC and other malignancies that have a good prognosis received surgery or radiotherapy for both or either malignant tumor. However, to the best of our knowledge, no study has reported that a patient with advanced stage in both NSCLC and another malignancy received the respective standard therapy for each malignant tumor concurrently.

Here, we report the case of a patient who, during treatment with the EGFR-TKI afatinib for LAD, developed malignant lymphoma and subsequently received R-CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisone with rituximab) while continuing treatment with afatinib.

2. Case report

A 64-year-old woman was diagnosed with stage IVB (T4N3M1c) \cite{4} LAD expressing mutant EGFR (exon 19 deletion) (Fig. 1-A). We administered afatinib (40 mg/day) as the first-line regimen. Three months after starting afatinib, the patient developed repeatedly grade 3 diarrhea (Common Terminology Criteria for Adverse Events version 4.0). Therefore, the afatinib dose was reduced to 20 mg/day until twenty-three months from starting afatinib, maintaining a partial response of the LAD (Fig. 1-B).

At the time of diagnosis of LAD, we detected abdominal lymphadenopathies by abdominal computed tomography (CT) imaging; however, we assessed them as metastases from the LAD (Fig. 1-C). During treatment with afatinib, abdominal lymphadenopathies and...
splenomegaly continued to increase on the CT image (Fig. 1-D). At the
time of starting afatinib therapy, complete blood count showed nor-
mality of differential white blood count and only thrombocytopenia
(white blood cells: 4500 [institutional normal range is 4000–8500]/μL;
neutrophils 3290/μL, lymphocytes 790/μL, hemoglobin: 11.1
[11.0–15.0] g/dL and platelet: 7.5 × 10⁴ [1.5–3.5 × 10⁵]/μL).

Thirty-two months after starting afatinib treatment, the patient was
admitted to the hospital due to acute abdominal distension. We de-
tected hepatosplenomegaly, ascites, and intra-abdominal lymphadeno-
pathies by abdominal CT (Fig. 1-E, F). The complete blood count re-
vealed elevated white blood cell (24900/μL) and lymphocyte counts
(21370/μL), including 87% of atypical lymphocytes that appeared
small and cleaved typically (Fig. 2-A); Hemoglobin decreased to 9.3 g/
dl, and thrombocyte count to 63000/μL. Immunohistochemistry of
atypical lymphocytes in peripheral blood revealed that they were po-
sitive for CD10, CD19, CD20, CD79a, and BCL-2 (Fig. 2-B, C, D, E), and
negative for CD3, CD4, CD5, and CD8 (not shown). On the basis of these
findings, we suspected that lymphoid malignancy coexisted with LAD.
Subsequent flow cytometry showed that the lymphoma cells were CD3-,
CD4-, CD5-, CD8-, CD10+, CD19+, CD20+, CD79a+, BCL-2+, and Ig-
k+. Similar findings were found in ascites and bone marrow. Fluores-
cence in situ hybridization of ascites revealed the translocation of IGH
and BCL2 (Fig. 2-F). These pathological features were consistent with
follicular lymphoma (FL). These findings, obtained by whole body
contrast-enhanced CT, immunohistochemistry and flow cytometry of
peripheral blood, ascites and bone marrow, and fluorescence in situ
hybridization of ascites suggested that the follicular lymphoma in-
filtrated her bone marrow. Therefore, we assessed her clinical stage was
stage IV of Ann Arbor classification [5] and high risk in FL international
prognostic index-2 [6]. Retrospectively, we diagnosed this case as FL
that was probably present before the diagnosis of LAD and developed
slowly while on treatment with afatinib for LAD. At first, we could not
ascertain whether intra-abdominal lymphadenopathies had resulted
from LAD or lymphoma. We considered it reasonable to continue
treatment with afatinib because the discontinuation of afatinib
would have led to a rapid exacerbation of LAD. Furthermore, she developed FL
with high tumor burden defined by GELF criteria [7]. Therefore, we
decided to concurrently administer immunochemotherapy for FL.

At first, we planned to perform R-CHOP (cyclophosphamide, dox-
orubicin, vincristine, and prednisone with rituximab) as the
first regimen for FL. However, we started CHOP alone to avoid infusion re-
action in the first cycle, and subsequently added rituximab to CHOP
from the second cycle.

After completing six-cycles of immunochemotherapy for FL, we
evaluated the therapeutic effects on LAD and FL, respectively. The
primary lesion of the LAD maintained reduced size but multiple small
LAD metastases occurred in both lung fields (Fig. 3-A). A T790M mu-
tation of the EGFR was detected by liquid biopsy, and therefore we
administered osimertinib as a second line treatment. Treatment of the
FL resulted in the disappearance of lymphoma cells in peripheral blood,
reduction of hepatosplenomegaly, and shrinking of swollen intra-ab-
dominal lymph nodes (Fig. 3-B), therefore we assessed that she
achieved a partial response. Accordingly, the patient’s performance
status improved.

3. Discussion

The diagnosis of multiple primary malignancies is in accordance
with the criteria developed by Warren and Gates [8]: each tumor must
be malignant; each tumor must have its own unique pathological fea-
tures; and metastasis or recurrence must be excluded. This case met
these criteria. Previous literature reported the rate of patients with lung
cancers and a second malignancy ranged from 0.9% to 26.3% [9-15].
Kim et al. [16] reviewed 1964 patient cases: of them, 47 patients (2.4%)
had a history of lymphoma; 6 (13%) had Hodgkin lymphoma; and 41 (87%) had non-Hodgkin lymphoma. Histology of lung cancers revealed that 28 patients (60%) had adenocarcinoma, 17 (36%) squamous cell carcinoma, and 2 (4%) other lung cancers [16]. In double-primary malignant tumors, it is common to select surgery or radiotherapy when one or both treatments can be curative; however, when both cancers are in advanced stage, no clear guideline for treatment exists. In such cases, it is common to select therapeutic strategies specific for the treatment of each respective tumor according to the guideline considering type and progression of each tumor.

In this report, we describe a case of FL developing during treatment of an EGFR mutation-positive LAD. Generally, FL progresses slowly and even in high-risk groups, the three-year survival rate is 84% [6]. However, the median overall survival is 27.9 months in EGFR mutation-positive LAD [17]. Therefore, the prognosis of our patient was defined by the LAD. However, we assessed that it was also necessary to treat the FL, because of worsening of the patient’s performance status due to high tumor burden. Therefore, we treated the patient concurrently for FL and LAD with R-CHOP and afatinib, respectively. We started the treatment for FL with CHOP alone to avoid infusion reaction in the first cycle because previous studies reported that bone marrow infiltration and higher circulating tumor lymphocyte counts were risk factors for infusion reaction [18,19], and patient’s performance status was poor. After confirming safety, we subsequently added rituximab from the second cycle to the sixth cycle and continued with rituximab alone for three cycles. Her performance status having been improved, we discontinued rituximab as a maintenance regimen to prevent delayed side effects such as immunosuppression. Considering the poorer prognosis of LAD, we should have prioritized the treatment for LAD with cytotoxic chemotherapies when afatinib therapy failed.

Despite an extensive literature search, we could not find any report on concurrent introduction of anti-cancer agents to several advanced malignant tumors. In most cases, it would be difficult to introduce each respective cytotoxic chemotherapy for multiple cancers; however, in this case, the toxicities of the molecular-targeted drug and the cytotoxic chemotherapy did not overlap. Therefore, we could simultaneously administer both the standard treatments for LAD and FL. Prognosis of LAD, particularly of EGFR or ALK mutation-positive LAD has been remarkably improved by the development of molecular-targeted drugs. Opportunities to treat double-malignant tumors as described in this case will increase from now on.

Funding

This research did not receive any specific grant from funding...
agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

T.H. has received lecture fees and research funding from Ono Pharmaceutical Co. Ltd. (Osaka, Japan), Lilly Japan Co. Ltd. (Hyogo, Japan), AstraZeneca Co. Ltd. (Osaka, Japan), Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan), Chugai Pharmaceutical Co. Ltd. (Tokyo, Japan), MSD Oncology Co. Ltd. (Tokyo, Japan), and Merck Serono Co. Ltd. (Tokyo, Japan). The remaining authors (K.M., G.K., S.T., N.H., H.T., S.M., A.T., T.S., N.M., H.S., N.O., and H.K.) declare no conflicts of interest.

Ethics approval and consent to participate

The Osaka Habikino Medical Center’s ethics committee approved this report (No. 841-1).

Patient consent for publication

Written informed consent is available.

Acknowledgements

Not applicable.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jrmcr.2019.100862.

References

[1] A. Inoue, K. Kobayashi, M. Marmomdo, S. Sugawara, S. Oizumi, H. Isebe, A. Gemma, M. Harada, H. Yoshizawa, I. Kinoshita, Y. Fujita, S. Koinaga, H. Hirano, K. Yoshihori, T. Harada, Y. Sajio, K. Hagiwara, S. Morita, T. Nukiwa, North-East Japan Study Group, Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002), Ann. Oncol. 24 (2012) 54–59 https://doi.org/10.1093/annonc/mds214.
[2] J.C. Soria, Y. Ohe, J. Vansteenkiste, T. Reungwetwattana, B. Chewaskulyong, K.H. Lee, A. Dechaphunkul, F. Imamura, N. Nogami, T. Kurata, I. Okamoto, C. Zhou, B.C. Cho, Y. Cheng, E.K. Cho, P.J. Voon, D. Planchard, W.C. Su, J.E. Gray, S.M. Lee, R. Hodge, M. Marotti, Y. Rukazenkov, S.S. Ramalingam, FLAURA Investigators, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N. Engl. J. Med. 378 (2018) 113–125 https://doi.org/10.1056/NEJMoa1715317.
[3] S. Peters, D.R. Camidge, A.T. Shaw, S. Gadgeel, J.S. Ahn, D.W. Kim, S.H.I. Ou, M. Péro, R. Dziedziozsuk, R. Roselli, A. Zeaiter, E. Mitry, S. Golding, B. Balas, J. Noe, P.N. Morcos, T. Mok, ALEX Trial Investigators, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer, N. Engl. J. Med. 377 (2017) 829–838 https://doi.org/10.1056/NEJMoa1704795.
[4] P. Goldstraw, K. Chansky, J. Crowley, R. Rami-Porta, H. Asamura, W.E. Eberhardt, A.G. Nicholson, P. Groome, A. Mitchell, V. Bolejcek, R. Rami-Porta, TheIASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer, J. Thorac. Oncol. 11 (2016) 39–51 https://doi.org/10.1097/JTO.0000000000000009.
[5] P.P. Carbone, H.S. Kaplan, K. Mushoff, D.W. Smithers, M. Tubiana, Report of the committee on Hodgkin’s disease staging classification, Cancer Res. 31 (1971) 1860–1861.
[6] M. Federico, M. Belloé, L. Marcheselli, S. Luminari, A. Lopez-Guillermo, U. Vitolo, B. Pro, S. Pileri, A. Pulsoni, P. Soubeyran, S. Cortelazzo, Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project, J. Clin. Oncol. 27 (2009) 4555–4562, https://doi.org/10.1200/JCO.2008.21.3991.
[7] C. Sebha, N. Mounier, N. Brousse, C. Belanger, P. Rice, C. Hainou, H. Tilly, P. Feugier, R. Bouabdallah, C. Doyen, G. Salles, Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA), Blood 108 (2006) 2540–2544 https://doi.org/10.1182/blood-2006-03-113193.
[8] S. Warren, O. Gates, Multiple primary malignant tumors: a survey of the literature and a statistical study, Am. J. Cancer 16 (1932) 1558–1541.
[9] C.S. Duchateau, M.P. Stokkel, Second primary tumors involving non-small-cell lung cancer: prevalence and its influence on survival, Chest 127 (2005) 1152–1158, https://doi.org/10.1378/chest.127.4.11152.
[10] R. Aguilo, F. Maciá, M. Porta, M. Casamitjana, J. Minguella, A.M. Novoa, Multiple independent primary cancers do not adversely affect survival of the lung cancer patient, Eur. J. Cardiothorac. Surg. 34 (2008) 1075–1080 https://doi.org/10.1016/j.ejcts.2008.08.004.
[11] C. Son, S.K. Lee, P.J. Choi, M.S. Roh, Characteristics of additional primary malignancies in Korean patients with non-small cell lung cancer, J. Thorac. Dis. 5 (2013) 737–744, https://doi.org/10.1186/1756-9567-5-737.
[12] M.V. Brock, A.J. Alberg, C.M. Hooker, A.L. Knammer, L. Xu, C.M. Roig, S.C. Yang, Risk of subsequent primary neoplasms developing in lung cancer patients with prior malignancies, J. Thorac. Cardiovasc. Surg. 127 (2004) 1119–1125 https://doi.org/10.1016/j.jtcvs.2003.10.039.
[13] Y.Y. Lin, Y.M. Chen, S.H. Yen, C.M. Tsai, R. Perng, Multiple primary malignancies involving lung cancer–clinical characteristics and prognosis, Lung Cancer 35 (2002) 189–194 http://dx.doi.org/10.1016/S0169-5002(01)00408-1.
[14] L. Teppo, E. Salminen, E. Pukkala, Risk of a new primary cancer among patients with lung cancer of different histological types, Eur. J. Cancer 37 (2001) 613–619 https://doi.org/10.1054/ejca.2000.05427.
[15] H. Kato, L. Randimbison, V.C. Te, C. La Vecchia, Second primary cancers in patients with lung carcinoma, Cancer 66 (1990) 186–190 https://doi.org/10.1002/(SICI)1097-0248(19900301)66:3<186::AID-CNCR25>3.0.CO;2-3.
[16] M.P. Kim, A.M. Correa, S.G. Swisher, D.C. Rice, G.L. Walsh Jr., J. Erasmus, C. Moran, A.A. Vapourciyan, J.A. Roth, Non-small cell lung cancer resection in lymphoma patients, Ann. Thorac. Surg. 90 (2010) 210–216 https://doi.org/10.1016/j.athoracsur.2010.02.114.
[17] L. Paz-Ares, E.H. Tan, K. O’Byrne, L. Zhang, V. Hirsh, M. Boyer, J.H. Yang, T. Mok, K.H. Lee, S. Lu, Y. Shi, Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIIb LUX-Lung 7 trial, Ann. Oncol. 28 (2017) 270–277 https://doi.org/10.1093/annonc/mdw611.
[18] J. Hong, J.Y. Kim, H.K. Ahn, S.M. Lee, S.J. Syn, J. Park, E.K. Cho, J.Y. Ahn, S.P. Lee, D. Shinll, Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma, Support Care Cancer 21 (2013) 1145–1152, https://doi.org/10.1007/s00520-012-1639-9.
[19] U. Winkler, M. Jensen, O. Manzke, H. Schulz, V. Diehl, A. Engert, Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8), Blood 94 (1999) 2217–2224.